EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
作者： Michael F Press , Heinz-Josef Lenz
DOI: 10.2165/00003495-200767140-00006
关键词:
摘要: … On the basis of preclinical and clinical evidence, EGFR, HER2 and VEGF represent … Both EGFR and HER2 are targets found on cancer cells, whereas VEGF is a target that acts in the …
springer.com
sci-hub.se 参考文章(163)
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. Journal of Clinical Oncology. ,vol. 24, pp. 370- 378 ,(2006) , 10.1200/JCO.2005.03.5196
C. R. King, I. Borrello, F. Bellot, P. Comoglio, J. Schlessinger, Egf binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3. The EMBO Journal. ,vol. 7, pp. 1647- 1651 ,(1988) , 10.1002/J.1460-2075.1988.TB02991.X
Lovell A. Jones, Jay George, Juan C. Felix, Adel El-Naggar, Bahman Saffari, Michael F. Press, Amplification and Overexpression of HER-2/neu (c-erbB2) in Endometrial Cancers: Correlation with Overall Survival Cancer Research. ,vol. 55, pp. 5693- 5698 ,(1995)
Andreas Gschwind, Oliver M. Fischer, Axel Ullrich, The discovery of receptor tyrosine kinases: targets for cancer therapy. Nature Reviews Cancer. ,vol. 4, pp. 361- 370 ,(2004) , 10.1038/NRC1360
Dieter Marmé, Joachim Drevs, Harald Hugenschmidt, Clemens Unger, Jeanette Wood, Georg Martiny-Baron, Helmut Madjar, Christine Wittig, Marianne Müller, Inga Hofmann, Effects of PTK787/ZK 222584, a Specific Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, on Primary Tumor, Metastasis, Vessel Density, and Blood Flow in a Murine Renal Cell Carcinoma Model Cancer Research. ,vol. 60, pp. 4819- 4824 ,(2000)
R M Shaheen, S A Ahmad, W Liu, N Reinmuth, Y D Jung, W W Tseng, K E Drazan, C D Bucana, D J Hicklin, L M Ellis, Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors British Journal of Cancer. ,vol. 85, pp. 584- 589 ,(2001) , 10.1054/BJOC.2001.1936
R. M. Bukowski, C. M. Baum, S. T. Kim, R. J. Motzer, T. E. Hutson, R. A. Figlin, M. D. Michaelson, P. Tomczak, S. Oudard, O. Rixe, Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) ASCO Meeting Abstracts. ,vol. 24, ,(2006)
HX Chen, M Mooney, M Boron, L Grochow, J Zwiebel, D Vena, K Mosby, C Grandinetti, RS Kaplan, None, Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301) Journal of Clinical Oncology. ,vol. 22, pp. 3515- 3515 ,(2004) , 10.1200/JCO.2004.22.90140.3515
J. A. Bonner, P. M. Harari, J. Giralt, J. Baselga, D. Shin, R. Cohen, J. Jassem, N. Azarnia, P. Molloy, K. K. Ang, Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx Journal of Clinical Oncology. ,vol. 23, pp. 5533- 5533 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.5533
Carlos L. Arteaga, The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. Journal of Clinical Oncology. ,vol. 19, ,(2001)